Page last updated: 2024-12-06

d,d-t80-prallethrin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

d,d-T80-prallethrin: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID31621
SCHEMBL ID2976330
MeSH IDM0156930

Synonyms (13)

Synonym
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methylpropenyl)-, ester with 4-hydroxy-3-methyl-2-(2-propynyl)-2-cyclopenten-1-one, trans-(+-)-
d.d-t80-prallethrin
2-methyl-4-oxo-3-(prop-2-ynyl)cyclopent-2-en-1-yl 2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropanecarboxylate
ai3-29750
cyclopropanecarboxylic acid, 2,2-dimethyl-3-(2-methyl-1-propenyl)-, cis,trans-(+)-, 2-methyl-4-oxo-3-(2-propynyl)-2-cyclopenten-1-yl ester
prallethrin [iso]
einecs 245-387-9
d,d-t80-prallethrin
(2-methyl-4-oxo-3-prop-2-ynylcyclopent-2-en-1-yl) (1s,3s)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate
hsdb 8169
2x67a9b2z7 ,
unii-2x67a9b2z7
SCHEMBL2976330

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"This study was carried out to evaluate the adverse effects of exposure to prallethrin on oxidant/antioxidant status and liver dysfunction biomarkers and the protective role of Origanum majorana essential oil (EO) in rat."( Amelioration of prallethrin-induced oxidative stress and hepatotoxicity in rat by the administration of Origanum majorana essential oil.
Bouajila, J; Mossa, AT; Ramadan, A; Refaie, AA, 2013
)
0.39
" We observe that the toxic effect of P-BI is more pronounced on transgenerational and lifespan exposure."( Household prallethrin-based insecticide toxicity on different C. elegans life stage: A possible sign of Huntington Disease.
Alves, C; Barcellos, LJG; Pompermaier, A; Tamagno, WA; Vanin, AP, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.23)18.7374
1990's2 (6.45)18.2507
2000's6 (19.35)29.6817
2010's17 (54.84)24.3611
2020's5 (16.13)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.75

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.75 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.75)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.23%)6.00%
Case Studies2 (6.45%)4.05%
Observational0 (0.00%)0.25%
Other28 (90.32%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]